AFFY Share Price

Open 0.03 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month -0.01 -25.00
Volume 10467 1 Year -0.05 -62.50
52 Week High 0.08
52 Week Low 0.00
AFFY Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.03
Support 1 0.03
Support 2 0.03
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Affymax, Inc. (NASDAQ: AFFY)

AFFY Technical Analysis 5
As on 30th Oct 2017 AFFY Share Price closed @ 0.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.06 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
AFFY Target for April
1st Target up-side 0.04
2nd Target up-side 0.04
3rd Target up-side 0.04
1st Target down-side 0.02
2nd Target down-side 0.02
3rd Target down-side 0.02
AFFY Other Details
Segment EQ
Market Capital 814314560.00
Sector Healthcare
Industry Biotechnology
Offical website
AFFY Address
19200 Stevens Creek Boulevard
Suite 240
Cupertino, CA 95014
United States
Phone: 650-812-8700
AFFY Latest News
Interactive Technical Analysis Chart Affymax, Inc. ( AFFY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Affymax, Inc.
AFFY Business Profile
Affymax, Inc., incorporated on July 20, 2001, is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a worldwide collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited (Takeda). As of December 31, 2011, over 2,600 patients have received peginesatide in clinical trials. As of December 31, 2011, The New Drug Application (NDA) for peginesatide is under review by the United States, Food and Drug Administration (FDA). As of December 31, 2011, the Company has suspended its development efforts to treat anemia in non-dialysis patients and chemotherapy-induced anemia. The Company and Takeda Pharmaceutical Company Limited completed multiple Phase I and Phase II clinical trials of peginesatide at sites in the United States and the European Union in normal healthy volunteers, dialysis patients, non-dialysis patients and peritoneal dialysis patients. These Phase I clinical trials were designed primarily to demonstrate bioavailability or bioequivalence of product concentrations and formulations while these Phase II trials were designed to determine the safety, pharmacodynamics and pharmacokinetics of peginesatide when administered to patients suffering from anemia. Two of these Phase II clinical trials were conducted to evaluate the use of peginesatide to treat anemic patients in additional segments of the chronic kidney disease patient population. One of the studies focused on evaluating peginesatide in patients undergoing peritoneal dialysis, a special form of dialysis that allows the process to be performed in the patient's home.Another trial was designed to evaluate the conversion of Aranesp-treated chronic kidney disease patients (on dialysis and not on dialysis) to once-monthly peginesatide. As of December 31, 2011, the Company continues to conduct an ongoing Phase II clinical trial of peginesatide in a small number of patients with pure red cell aplasia (PRCA) in European Union.